摘要
由于分枝杆菌结核病家族对于传统治疗方法的阻力越来越大,防治结核病变得越来越难。因此,我们需要分离出新的药物靶点,并且随后设计出该药品的特效抑制剂。在细菌、藻类、植物和真菌中、支链氨基酸(BCAA)的合成是由乙酰羟酸合成酶(AHAS)酶组催化完成的。细菌AHAS利用辅酶因子如二磷酸硫胺(ThDP),黄素腺嘌呤二核苷酸(FAD)和二价金属阳离子(通常是镁离子)等,来催化异亮氨酸、亮氨酸和缬氨酸的生物合成。该酶的合成代谢形式现在正在讨论中。其形式被认为事实上包括两个亚单位,一个起催化作用,一个起调节作用。该酶催化反应的产物分别是由丙酮酸盐自缩合或由丙酮酸盐和2-丁酮酸缩合获得的2-乙酰乳酸盐或2-乙酰-2-羟基丁酸盐。这些产物会被一系列其他酶转化为BCAA。AHAS催化的阶段是整个流程的开始,然后该阶段可以被该途径的抑制途径选择性地针对。被编码为 ilvB 和 ilvN 操纵子的分枝杆菌结核病AHAS在结构上与大肠杆菌AHAS相关,且功能相似。因此,属于磺脲类,咪唑啉酮类和苯甲酰酯的特效药可作为分枝杆菌结核病AHAS抑制剂,这些抑制剂最终会耗尽细菌的BCAA供给,从而高效抑菌。
关键词: 乙酰羟酸合成酶,AHAS抑制剂,苯甲酰酯,支链氨基酸,咪唑啉酮,磺脲。
图形摘要
Current Drug Targets
Title:Mechanisms of bacterial acetohydroxyacid synthase (ahas) and specific inhibitors of Mycobacterium tuberculosis ahas as potential drug candidates against tuberculosis
Volume: 16 Issue: 7
Author(s): Kunal Gokhale and Bhargav Tilak
Affiliation:
关键词: 乙酰羟酸合成酶,AHAS抑制剂,苯甲酰酯,支链氨基酸,咪唑啉酮,磺脲。
摘要: On account of the ever increasing resistance of M.tuberculosis strains to orthodox therapy regimens, the task of combating tuberculosis becomes even more challenging. Therefore, there arises a need to isolate new drug targets and subsequently design specific inhibitors for the same. In bacteria, algae, plants and fungi, the synthesis of Branched Chain Amino Acids (BCAAs) is catalyzed by Acetohydroxyacid Synthases (AHAS) group of enzymes. Bacterial AHAS (EC 2.2.1.6) catalyzes the biosynthesis of isoleucine, leucine and valine by utilizing cofactors like Thiamin Diphosphate (ThDP), Flavin Adenine Dinucleotide (FAD) and a divalent metal cation (Usually Mg2+). The anabolic form of the enzyme which is presently under discussion consists of two subunits out of which one is catalytic while the other is regulatory in nature. The product of this enzyme catalyzed reaction is either 2-acetolactate or 2-aceto-2-hydroxybutyrate obtained from self-condensation of pyruvate or condensation of puruvate and 2-ketobutyrate, respectively. These are further converted to the BCAAs by a series of other enzymes. The step catalyzed by AHAS is the first in the entire cascade and hence can be selectively targeted for the inhibition of this pathway. M.tuberculosis AHAS, which is encoded by the ilvB and ilvN operons is structurally related to E.coli AHAS and has a similar function. Therefore, specific drugs belonging to the classes of sulfonylureas, imidazolinones and benzoyl esters can be used as inhibitors of M.tuberculosis AHAS which would consequently deplete the BCAA supply to the bacteria. Thus, efficient bacteriostasis can be achieved.
Export Options
About this article
Cite this article as:
Kunal Gokhale and Bhargav Tilak , Mechanisms of bacterial acetohydroxyacid synthase (ahas) and specific inhibitors of Mycobacterium tuberculosis ahas as potential drug candidates against tuberculosis, Current Drug Targets 2015; 16 (7) . https://dx.doi.org/10.2174/1389450116666150416115547
DOI https://dx.doi.org/10.2174/1389450116666150416115547 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toward the Virtual Screening of Potential Drugs in the Homology Modeled NAD+ Dependent DNA Ligase from Mycobacterium tuberculosis
Protein & Peptide Letters Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters The Bacterial lux Reporter System: Applications in Bacterial Localisation Studies
Current Gene Therapy Prevalence of Oral and Systemic Manifestations in Pediatric HIV Cohorts with and without Drug Therapy
Current HIV Research Editorial (Thematic Issue: Recent Trends in Library Design and Virtual Screening in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry The Inhibition of 5-enolpyruvylshikimate-3-phosphate Synthase as a Model for Development of Novel Antimicrobials
Current Drug Targets Subject Index To Volume 8
Current Pharmaceutical Design Exploring Promising Immunomodulatory Potential of Natural and Synthetic 1,3-Diphenyl-2-propen-1-one Analogs: A Review of Mechanistic Insight
Mini-Reviews in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Dynamics Simulation Studies of Novel Diphenyl Ethers
Medicinal Chemistry Pharmacological Aspects and Potential Use of Phloretin: A Systemic Review
Mini-Reviews in Medicinal Chemistry Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets Bioinformatics and the Discovery of Novel Anti-Microbial Targets
Current Drug Targets - Infectious Disorders α-Glucan Pathway as a Novel Mtb Drug Target: Structural Insights and Cues for Polypharmcological Targeting of GlgB and GlgE
Current Medicinal Chemistry Exploiting Quorum Sensing Inhibition for the Control of Pseudomonas aeruginosa and Acinetobacter baumannii Biofilms
Current Topics in Medicinal Chemistry iATP: A Sequence Based Method for Identifying Anti-tubercular Peptides
Medicinal Chemistry Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Antistaphylococcal Activity of Novel Salicylanilide Derivatives
Current Drug Discovery Technologies